Regulus reports Q2 EPS (37c), consensus (41c)

“Our phase 1b MAD study of RGLS8429 continues to progress with dosing of the first patient in the second cohort, and we look forward to sharing top-line data from the first cohort in the coming months,” said Jay Hagan, CEO of Regulus. “I would like to extend a warm welcome to our recent leadership hires, Preston Klassen M.D. and Curtis A. Monnig, Ph.D., who are already making meaningful contributions to Regulus and our R&D efforts. Lastly, we continue to be excited by the progress in our preclinical program in Amyotrophic Lateral Sclerosis in collaboration with Brigham and Women’s Hospital. This has been another productive quarter for Regulus, and we look forward to providing further updates in the coming quarters.”